MAPK3 and diffuse large B-cell lymphoma: Importantly, our findings illuminate the potential of lenalidomide as a targeted therapy to inhibit the CCR7-CCL21/ERK1/2 axis, offering a promising avenue to mitigate DLBCL progression.